Results 31 to 40 of about 2,492,664 (191)

Evolution of anti- CD20 monoclonal antibody therapeutics in oncology [PDF]

mAbs, 2010
Approval of an anti-CD20 chimeric monoclonal antibody, rituximab, has revolutionized cancer treatment and also validated CD20 targeting for providing benefit and improvement of overall response rate in B cell malignancies. Although many patients have benefited from the treatment of rituximab, there are still significant numbers of patients who are ...
Ezogelin, Oflazoglu, Laurent P, Audoly
openaire   +2 more sources

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of severe refractory Anti-N-methyl-D-aspartate receptor encephalitis: Two case reports

Annals of Indian Academy of Neurology, 2023
Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a type of autoimmune encephalitis (AE) characterized by antibodies against NMDA receptor. As the most common AE, anti-NMDAR encephalitis affects 54% ~ 80% of patients with AE.
Hongfei Xue, Yushu Jiang, Lingzhi Qin, Xiaojuan Wang, Milan Zhang, Shuhua Dai, Yongshi Teng, Jiajia Xu, Wei Li   +8 more
doaj   +1 more source

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

, 2010
Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance ...
French, R.R., Johnson, P.W.M., Cox, Kerry L., Chan, Claude H.T., Johnston, David A., Glennie, Martin J., Jarrett, T.C., Glennie, M.J., Verbeek, Sjef, Chan, H.T.C., Dixon, S.V., Mora Vidal, Regina, Wijayaweera, Sahan S., Cragg, Mark S., Lim, Sean H., Dixon, Sandra V., Verbeek, J.S., French, Ruth R., Wijayaweera, S.S., Jarrett, Timothy C., Cragg, M.S., Kim, Hyung J., Kerr, Jonathan P., Vidal, R.M., Johnston, D.A., Lim, S.H., Cox, K.L., Kerr, J.P., Johnson, Peter W.M., Beers, Stephen A., Kim, H., Beers, S.A.   +31 more
core   +1 more source

T Cell Delivery of Nanoparticles-Bound Anti-CD20 Monoclonal Antibody: Successful B Cell Depletion in the Spinal Cord during Experimental Autoimmune Encephalomyelitis

, 2021
We developed a nanotechnology based-cell mediated drug delivery system by loading myelin antigen-specific T cells with nanoparticles bound to anti-CD20 monoclonal antibody.
Amoriello, Roberta, Carnasciali, Alberto, Ravagli, Costanza, Bonechi, Elena, Doumett, Saer, Mazzoni, Alessio, D’Elios, Mario Milco, Ballerini, Clara, Baldi, Giovanni, Cappiello, Laura   +9 more
core   +1 more source

The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma

, 2010
Recent improvements in molecular sub typing of Non Hodgkin’s lymphomashave resulted in targeted therapies becoming incorporated into treatmentparadigms.
Nolan, David Francis Luke
core   +2 more sources

Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anaemia

, 2001
Immune-mediated, acquired pure red cell aplasia (PRCA) is a rare disorder frequently associated with other autoimmune phenomena. Conventional immunosuppressive treatment is often unsatisfactory. Rituximab is a monoclonal antibody against the CD20 antigen,
LOCATELLI, FRANCO, P. DESTEFANO, ZECCA M, B. NOBILI   +3 more
core   +3 more sources

A case of chronic myelomonocytic leukemia complicated with immune thrombocytopenia

Shanghai Jiaotong Daxue xuebao. Yixue ban
Chronic myelomonocytic leukemia (CMML) complicated with immune thrombocytopenia (ITP) is rare. This article reports the clinical data of a patient with CMML complicated with ITP treated with a combination of venetoclax, ripertamab (an anti-CD20 ...
LIU Jiayu, HUANG Fang, HAO Siguo
doaj   +1 more source

Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans [PDF]

, 2013
Rabies kills many people throughout the developing world every year. The murine monoclonal antibody (mAb) 62-71-3 was recently identified for its potential application in rabies postexposure prophylaxis (PEP).
Both, L, Bulmer-Thomas, B., Banyard, AC, Selden, D., Altmann, F, Craig van Dolleweerd (406086), David Selden (4911475), Selden, D, Ashley C Banyard (16267520), Both, L., Banyard, A.C., Edward Wright (4468198), Bulmer-Thomas, B, Fooks, AR, Friedrich Altmann (33138), Wright, E, van Dolleweerd, C., Fooks, A.R., Ma, J.K.C., Julian K C Ma (16267529), Leonard Both (16267517), van Dolleweerd, C, Ma, JK, Wright, E., Altmann, F., Anthony R Fooks (16267526), Bianca Bulmer-Thomas (16267523)   +26 more
core   +1 more source

On the aggregation and nucleation mechanism of the monoclonal antibody anti-CD20 near liquid-liquid phase separation (LLPS) [PDF]

, 2020
The crystallization of Anti-CD20, a full-length monoclonal antibody, has been studied in the PEG400/Na2SO4/Water system near Liquid-Liquid Phase Separation (LLPS) conditions by both sitting-drop vapour diffusion and batch methods.
Nicoletta, Fiore P., Gerard, Charline J. J., Mastropietro, Teresa F., Curcio, Efrem, Briuglia, Maria L., Di Profio, Gianluca, Pantuso, Elvira, ter Horst, Joop H., Briuglia ML, Mastropietro TF, Pantuso E, ter Horst JH, Di Profio G, Curcio E, Gerard CJJ, Nicoletta FP   +15 more
core   +1 more source

Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells

Frontiers in Immunology, 2021
One mechanism by which monoclonal antibodies (mAb) help treat cancer or autoimmune disease is through triggering antibody-dependent cellular cytotoxicity (ADCC) via CD16 on Natural Killer (NK) cells.
Alexandros Karampatzakis, Petr Brož, Camille Rey, Björn Önfelt, Björn Önfelt, Gabriela Dos Santos Cruz De Matos, Daniel Rycroft, Ashley Ambrose, Daniel M. Davis   +8 more
doaj   +1 more source